In utero Treatments of Congenital Dental and Craniofacial Disorders Using Precision Medicine Approaches (R21 Clinical Trial Not Allowed) | RFA DE 23 005

Frequently Asked Questions (FAQs)

What is the title and ID of this funding opportunity?

The opportunity is titled "In utero Treatments of Congenital Dental and Craniofacial Disorders Using Precision Medicine Approaches (R21 Clinical Trial Not Allowed)" and the funding opportunity number is RFA-DE-23-005.

What type of funding is this?

This is an NIH discretionary grant program. The funding instrument type is a Grant, and the funding activity category is Health.

What research stage is this opportunity meant to support?

It uses the R21 mechanism, which is intended for early-stage, exploratory, and developmental research. The emphasis is on innovative ideas and proof-of-concept studies rather than large, definitive programs.

What is the overarching goal of this program?

The goal is to accelerate early, preclinical research that develops and tests potential fetal (in utero) interventions for congenital dental and craniofacial disorders, building a foundation that could eventually support safe and effective prenatal therapies in humans.

What conditions are within scope?

The scientific focus is congenital dental and craniofacial disorders, meaning conditions present before birth that disrupt development of the teeth, jaws, face, and related craniofacial structures.

What does "in utero treatment" mean in this context?

In this context, it refers to prenatal interventions delivered during fetal development, studied in preclinical systems, to influence developmental outcomes related to congenital dental or craniofacial disorders.

Are clinical trials allowed under this opportunity?

No. The announcement explicitly states that clinical trials are not allowed under this funding opportunity.

If clinical trials are not allowed, what kinds of studies are expected?

The program is centered on preclinical work, particularly in animal models, aimed at generating evidence needed to reduce risk for future translation. Examples of expected study themes (as described) include feasibility of fetal delivery, developmental timing, dosing considerations, safety signals, durability of effect, and measurable improvements in craniofacial or dental developmental outcomes in the model system.

Are animal models required or strongly encouraged?

Animal models are described as central to the approach. Proposed studies are expected to be conducted in relevant preclinical systems where fetal development can be observed and manipulated, and where prenatal delivery routes, timing, dosing, safety, and outcomes can be evaluated.

What does "precision medicine approaches" mean for applicants?

Precision medicine approaches, as described here, mean considering biological variability and disease mechanisms in a more individualized or mechanism-driven way. This often points toward linking genotype to phenotype, stratifying disease subtypes, or using molecular and developmental information to tailor a therapeutic approach.

Does this opportunity focus on studying disease mechanisms, or on developing treatments?

The stated intent is not simply to study these disorders, but to accelerate development of treatment strategies that could plausibly be translated to prenatal care in the future.

What are examples of "precision" elements that might fit the program description?

Based on the description provided, examples include genotype-informed treatment design, molecular targeting, mechanistic stratification of disease subtypes, and tailoring intervention strategies using molecular and developmental information.

What kind of outcomes or endpoints are aligned with the program intent?

The description highlights outcomes such as feasibility of fetal delivery, appropriate developmental timing, safety signals, durability of effect, and measurable improvements in craniofacial or dental developmental outcomes in the chosen animal model system.

What is the CFDA number associated with this opportunity?

The associated CFDA number is 93.121.

When was this opportunity created and what closing date is listed?

The opportunity is listed as created on 2022-02-16, with an original closing date of 2022-06-14.

Is the award ceiling or number of awards specified in the provided information?

No. The source information provided does not specify an award ceiling or the expected number of awards.

Where would applicants typically look for typical budget ranges or project period expectations?

Based on the information provided, applicants would typically consult the full funding announcement or NIH budget guidance for the R21 mechanism to understand typical budget ranges, project period expectations, and any institute-specific constraints.

Who is eligible to apply?

Eligibility is broad. The provided list includes: state, county, and city/township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; public housing authorities/Indian housing authorities; Native American tribal organizations other than federally recognized tribal governments; nonprofit organizations with or without 501(c)(3) status (as long as they are not institutions of higher education, based on the listing); for-profit organizations other than small businesses; small businesses; and other entities.

Are minority-serving institutions and community-based organizations included in eligibility?

Yes. The opportunity explicitly highlights additional eligible categories including Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, HBCUs, TCCUs, and faith-based or community-based organizations.

Are federal agencies or regional organizations eligible?

Yes. The description includes eligible agencies of the federal government and regional organizations among the explicitly highlighted eligible applicant categories.

Are U.S. territories eligible to apply?

Yes. U.S. territories or possessions are explicitly listed among the highlighted eligible applicant categories.

Are non-U.S. (foreign) organizations eligible?

Yes. The description explicitly includes non-domestic (non-U.S.) entities (foreign organizations) as eligible.

What would a strong application generally include, based on the description?

A strong application would be expected to propose a clear, biologically grounded prenatal intervention concept for a congenital dental or craniofacial condition, justify the animal model(s), and explain how precision medicine elements (such as molecular targeting, mechanistic stratification, or genotype-informed design) increase the likelihood of meaningful translation.

What is the longer-term impact this program is trying to enable?

The longer-term objective is to build the scientific foundation needed to eventually deliver safe and effective in utero therapies in humans, even though the funded work itself must remain preclinical under this opportunity.